Dogs weighing less than 8 lbs (3.6 kg) cannot be accurately dosed. Only the 20 mg and 60 mg tablets of Galliprant® (grapiprant tablets) are scored. Dosages should be calculated in half-tablet increments, except when using the 100 mg tablet because it is not scored and should not be broken in half. For dogs weighing more than 150 lbs (68 kg), use a combination of tablets and half tablets to achieve the appropriate dose.
Prescribing Galliprant® (grapiprant tablets)
Prescribing Galliprant to your patients is easy.
Dosing and Administration
The dose for Galliprant is 0.9 mg/lb (2 mg/kg) once daily. The safe use of Galliprant has not been evaluated in dogs younger than 9 months of age.
Most dogs can be dosed with a whole or half a tablet once a day for effective canine OA pain relief (dogs weighing less than 8 lbs (3.6 kg) cannot be accurately dosed). You should prescribe Galliprant® in half-tablet increments, except when using the 100mg tablet – this should not be broken in half.
Pet Weight
or
| Weight (lbs): 8 - 15 | 20mg Tablet 0.5 |
| Weight (lbs): 15.1 - 30 | 20mg Tablet 1 |
| Weight (lbs): 30.1 - 45 | 60mg Tablet 0.5 |
| Weight (lbs): 45.1 - 75 | 60mg Tablet 1 |
| Weight (lbs): 75.1 - 150 | 100mg Tablet 1 |
| Weight (lbs) | 20mg Tablet | 60mg Tablet | 100mg Tablet |
|---|---|---|---|
| 8 - 15 | 0.5 | ||
| 15.1 - 30 | 1 | ||
| 30.1 - 45 | 0.5 | ||
| 45.1 - 75 | 1 | ||
| 75.1 - 150 | 1 |
Indication
Galliprant is an NSAID that controls pain and inflammation associated with osteoarthritis in dogs.
Important Safety Information
Not for use in humans. For use in dogs only. Keep this and all medications out of reach of children and pets. Store out of reach of dogs and other pets in a secured location in order to prevent accidental ingestion or overdose. Do not use in dogs that have a hypersensitivity to grapiprant. If Galliprant is used long term, appropriate monitoring is recommended. Concomitant use of Galliprant with other anti-inflammatory drugs, such as COX-inhibiting NSAIDs or corticosteroids, should be avoided. Concurrent use with other anti-inflammatory drugs or protein-bound drugs has not been studied. The safe use of Galliprant has not been evaluated in dogs younger than 9 months of age and less than 8 lbs (3.6 kg), dogs used for breeding, pregnant or lactating dogs, or dogs with cardiac disease. The most common adverse reactions were vomiting, diarrhea, decreased appetite, and lethargy. Click here for full prescribing information.
Contact your Elanco or distributor representative, or call Elanco (1-888-545-5973) to discover how you can incorporate Galliprant into your canine OA protocol today.
© 2022 Elanco or its affiliates. Galliprant, Elanco and the diagonal bar logo are trademarks of Elanco or its affiliates.
PM-US-19-1927(3)